Review

SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists

Rahul Jaswaney, MD, Samantha Sokoloff, MD, Val Rakita, MD and Daniel J. Rubin, MD, MSc
Cleveland Clinic Journal of Medicine July 2024, 91 (7) 415-423; DOI: https://doi.org/10.3949/ccjm.91a.23093

Article Information

vol. 91 no. 7 415-423
DOI 
https://doi.org/10.3949/ccjm.91a.23093
PubMed 
38950981
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online July 1, 2024.
Copyright & Usage 
Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Rahul Jaswaney, MD
  1. Fellow, Section of Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
  1. Samantha Sokoloff, MD
  1. Fellow, Section of Endocrinology, Diabetes and Metabolism, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
  1. Val Rakita, MD
  1. Associate Professor of Medicine; Associate Medical Director, Mechanical Circulatory Support Program; Director, CardioMEMS Program, Advanced Heart Failure, MCS, and Transplant Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
  1. Daniel J. Rubin, MD, MSc⇑
  1. Professor of Medicine, Interim Co-Director for the Center for Biostatistics and Epidemiology, Director of Clinical Research, and Deputy Chief, Section of Endocrinology, Diabetes and Metabolism, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
  1. Address:
    Daniel J. Rubin, MD, MSc, Lewis Katz School of Medicine at Temple University, Medical Office Building 3322 N. Broad Street, Suite 205, Philadelphia, PA 19140; Daniel.rubin{at}tuhs.temple.edu
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects